Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Lymphoma
Do we need to continue dose escalations wtih DA REPOCH after a negative interim PET scan for PMBCL?
Related Questions
How would you approach a patient with lymphoma (i.e. DLBCL) who has developed chylous pleural effusions while on therapy?
What is the best treatment approach to a patient with HGBCL w/ FISH translocation of BCL-6 and c-Myc given new classification of this entity?
How do you approach frontline treatment for an elderly patient with adult T-cell leukemia-lymphoma (ATL)?
How would you treat an elderly patient with Stage IIA cHL with 3 nodal sites of involvement who has a contraindication to bleomycin?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
How would you manage a patient with marginal zone lymphoma who progress after treatment on a BKTI?
How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?
What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
